​

Arcus Biosciences (RCUS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RCUS Stock Forecast

Arcus Biosciences (RCUS) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $30.60, with a high of $46.00 and a low of $20.00. This represents a 128.19% increase from the last price of $13.41.

$10 $18 $26 $34 $42 $50 High: $46 Avg: $30.6 Low: $20 Last Closed Price: $13.41

RCUS Stock Rating

Arcus Biosciences stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (57.14%), 3 Hold (42.86%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 3 4 Strong Sell Sell Hold Buy Strong Buy

RCUS Price Target Upside V Benchmarks

TypeNameUpside
StockArcus Biosciences128.19%
SectorHealthcare Stocks 24.61%
IndustryBiotech Stocks 65.94%

Price Target Trends

1M3M12M
# Anlaysts--8
Avg Price Target--$32.13
Last Closing Price$13.41$13.41$13.41
Upside/Downside--139.60%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 25283--13
Jan, 25283--13
Dec, 24283--13
Nov, 24283--13
Oct, 24383--14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 24, 2024Yigal NochomovitzCitigroup$46.00$17.42164.06%243.03%
Oct 21, 2024Emily BodnarH.C. Wainwright$20.00$18.448.46%49.14%
Oct 08, 2024Judah FrommerMorgan Stanley$35.00$18.0893.58%161.00%
Oct 08, 2024Eva Fortea VerdejoWells Fargo$29.00$18.0860.40%116.26%
Aug 09, 2024Jason ZemanskyBank of America Securities$23.00$13.6968.01%71.51%
Jul 08, 2024Peter LawsonBarclays$25.00$14.0078.57%86.43%
Jun 24, 2024Asthika GoonewardeneTruist Financial$44.00$16.45167.48%228.11%
Jun 04, 2024Peter LawsonBarclays$35.00$16.15116.72%161.00%
Dec 20, 2022Citigroup$42.00$20.66103.29%213.20%
Nov 23, 2022Citigroup$37.00$27.0037.04%175.91%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 24, 2024CitigroupBuyBuyhold
Oct 21, 2024Wells FargoNeutralNeutralhold
Oct 21, 2024H.C. WainwrightNeutralinitialise
Oct 08, 2024Morgan StanleyUnderperformOverweightinitialise
Oct 08, 2024Wells FargoOverweightinitialise
Oct 03, 2024WedbushNeutralNeutralhold
Aug 09, 2024Bank of America SecuritiesNeutralNeutralhold
Jul 08, 2024WedbushBuyBuyhold
Jul 08, 2024BarclaysOverweightOverweighthold
Jul 05, 2024Cantor FitzgeraldOverweightOverweighthold

Financial Forecast

EPS Forecast

$-9 $-7 $-5 $-3 $-1 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.13$0.76$-4.87$-4.15-----
Avg Forecast$-2.18$-4.35$-3.88$-4.00$-3.41$-4.33$-4.39$-4.67$-1.29
High Forecast$-3.89$-7.76$-8.27$-4.18$-4.16$-5.95$-6.57$-7.29$-3.73
Low Forecast$-1.24$-2.48$-1.30$-3.89$-2.61$-3.13$-1.95$-2.65$0.11
Surprise %-2.29%-117.47%25.52%3.75%-----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$77.52M$382.88M$112.00M$117.00M-----
Avg Forecast$75.97M$40.33M$102.64M$113.67M$246.83M$224.94M$244.84M$260.13M$635.46M
High Forecast$50.88M$27.01M$50.13M$109.48M$233.02M$46.21M$242.52M$250.13M$105.36M
Low Forecast$121.83M$64.67M$191.93M$119.63M$256.90M$484.46M$247.16M$270.13M$1.57B
Surprise %2.04%849.43%9.12%2.93%-----

Net Income Forecast

$-1B $-400M $200M $800M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-116.68M$53.00M$-267.00M$-307.00M-----
Avg Forecast$-92.57M$1.59B$1.43B$-307.00M$-270.00M$-385.92M$-416.98M$-429.11M$-95.16M
High Forecast$-112.01M$1.20B$1.05B$-392.35M$-307.63M$-440.36M$-485.96M$-539.65M$-276.34M
Low Forecast$-73.14M$1.98B$1.80B$-221.65M$-193.25M$-231.63M$-144.22M$-195.92M$8.04M
Surprise %26.04%-96.66%-118.73%------

RCUS Forecast FAQ

Is Arcus Biosciences stock a buy?

Arcus Biosciences stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Arcus Biosciences is a favorable investment for most analysts.

What is Arcus Biosciences's price target?

Arcus Biosciences's price target, set by 7 Wall Street analysts, averages $30.6 over the next 12 months. The price target range spans from $20 at the low end to $46 at the high end, suggesting a potential 128.19% change from the previous closing price of $13.41.

How does Arcus Biosciences stock forecast compare to its benchmarks?

Arcus Biosciences's stock forecast shows a 128.19% upside, outperforming the average forecast for the healthcare stocks sector (24.61%) and outperforming the biotech stocks industry (65.94%).

What is the breakdown of analyst ratings for Arcus Biosciences over the past three months?

  • February 2025: 15.38% Strong Buy, 61.54% Buy, 23.08% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 15.38% Strong Buy, 61.54% Buy, 23.08% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 15.38% Strong Buy, 61.54% Buy, 23.08% Hold, 0% Sell, 0% Strong Sell.

What is Arcus Biosciences’s EPS forecast?

Arcus Biosciences's average annual EPS forecast for its fiscal year ending in December is $-3.41 for 2024, a -17.83% decrease from the reported $-4.15 in 2023. The prediction for 2025 is $-4.33, $-4.39 for 2026, $-4.67 for 2027, and $-1.29 for 2028.

What is Arcus Biosciences’s revenue forecast?

Arcus Biosciences's average annual revenue forecast for its fiscal year ending in December is $246.83M for 2024, a 110.97% increase from the reported $117M in 2023. The forecast for 2025 is $224.94M, $244.84M for 2026, $260.13M for 2027, and $635.46M for 2028.

What is Arcus Biosciences’s net income forecast?

For its fiscal year ending in December, Arcus Biosciences's average annual net income forecast is $-270M for 2024, reflecting a -12.05% decrease from the reported $-307M in 2023. The projection for 2025 is $-386M, $-417M for 2026, $-429M for 2027, and $-95.164M for 2028.